The Risk of Acute Pancreatitis and Selective Serotonin Reuptake Inhibitors Use: A Meta-Analysis of Case-Control Studies

Shih-Wei Lai; Cheng-Chan Yu; Cheng-Li Lin; Kuan-Fu Liao

doi:10.1177/1559325820902352

The Risk of Acute Pancreatitis and Selective Serotonin Reuptake Inhibitors Use: A Meta-Analysis of Case-Control Studies

Dose Response. 2020 Mar 30;18(1):1559325820902352. doi: 10.1177/1559325820902352. eCollection 2020 Jan-Mar.

Authors

Shih-Wei Lai^{1

2}, Cheng-Chan Yu³, Cheng-Li Lin⁴, Kuan-Fu Liao^{5

6}

Affiliations

¹ College of Medicine, China Medical University, Taichung.
² Department of Family Medicine, China Medical University Hospital, Taichung.
³ Department of General Surgery, Taichung Tzu Chi Hospital, Taichung.
⁴ Management Office for Health Data, China Medical University Hospital, Taichung.
⁵ College of Medicine, Tzu Chi University, Hualien.
⁶ Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung.

Abstract

Background/objective: Some case series and case report have shown the association between the risk of acute pancreatitis and use of selective serotonin reuptake inhibitors. The results of systematic studies were not consistent.

Methods: A meta-analysis was performed to investigate the risk of acute pancreatitis associated with use of selective serotonin reuptake inhibitors.

Results: There was no statistical association between the risk of acute pancreatitis and selective serotonin reuptake inhibitors use (odds ratio: 1.19, 95% confidence interval: 0.93-1.51).

Conclusions: Despite reaching no statistical significance, the possibility of the association between the risk of acute pancreatitis and selective serotonin reuptake inhibitors use cannot be totally excluded.

Keywords: acute pancreatitis; selective serotonin reuptake inhibitors.